<div id="readability-page-1"><div><p>(MT Newswires) -- Centene (CNC) expects all of its business segments to improve in 2026 as the company continues to focus on driving margin across its portfolio after reaffirming its 2025 adjusted earnings per share guidance and providing &#34;positive commentary&#34; in key business lines, Truist Securities said in a Friday note.</p><p> In a recent conference presentation, Centene highlighted the incremental progress in its health benefits ratio for Medicaid, in line with its target of H2 segment ratio improvement. For its Marketplace segment, Centene has refiled rates in states covering about 95% of its membership, a majority of which have already been approved, Truist said.</p><p> For Medicare, preliminary data indicate Stars trends to be in-line with management's expectations, with a possibility for 4-Star plans membership percentage to be &#34;a bit better than expected,&#34; the investment firm added.</p><p> &#34;While the environment continues to carry areas of uncertainty we are encouraged by the company's update,&#34; Truist said.</p><p> Truist raised its price target on Centene to $39 from $35 and reiterated its buy rating.</p><p>Price: 33.99, Change: -0.09, Percent Change: -0.26</p></div></div>

康西哥

<p>Centene (CNC) 預計到 2026 年所有業務部門將實現改善，重點關注利潤提升。根據 Truist Securities 的報告，該公司重申了 2025 年調整後每股收益的指引，並收到了對關鍵業務線的積極反饋。醫療補助的健康福利比率的進展符合目標，大多數重新提交的市場費率已獲得批准。醫療保險的星級趨勢符合預期，4 星計劃有潛力超出預期。Truist 將 Centene 的目標股價從 35 美元上調至 39 美元，維持買入評級。當前股價：33.99 美元，下跌 0.26%</p>

Truist 證券表示，康西哥預計其業務板塊將在 2026 年有所改善